On October 7, Bailing Tianheng (688506.SH) announced that its independently developed innovative biopharmaceutical BL-B01D1 for injection is included in the list of breakthrough therapeutic varieties by the National Medical Products Administration Drug Evaluation Center (referred to as the "Drug Evaluation Center") for the two indications. The first indication is for locally advanced or metastatic non-squamous non-small cell lung cancer patients with EGFR-sensitive mutations who have failed EGFR-TKI treatment, and the second indication is for locally advanced or metastatic EGFR wild-type non-small cell lung cancer patients who have previously failed treatment with anti-PD-1/PD-L1 monoclonal antibodies and platinum-based chemotherapy. The details of the announcement are as follows:
